Citation Impact
Citing Papers
HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help
2003 StandoutScienceNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma
2008
Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy
2012 StandoutScienceNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
1990 Nature
Inflammation and cancer
2002 StandoutNature
High-Titer HIV-1 Neutralizing Antibody Response of Rhesus Macaques to gp160 and env Peptides
1992
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination
2009
Vasculogenic Mimicry and Tumor Angiogenesis
2000
Alteration of HIV-1 Infectivity and Neutralization by a Single Amino Acid Replacement in the V3 Loop Domain
1991
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Clinical translation of angiogenesis inhibitors
2002 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
2002
Antibody Responses of Chimpanzees Immunized with Synthetic Peptides Corresponding to Full-Length V3 Hypervariable Loops of HIV-1 Envelope Glycoproteins
1991
Tumor angiogenesis: past, present and the near future
2000
Induction of Broadly Cross-Reactive Cytotoxic T Cells Recognizing an HIV-1 Envelope Determinant
1992 Science
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
2005
Lack of Protective Immunity Against Reinfection with Hepatitis C Virus
1992 Science
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
Cancer Modeling in the Modern Era
2002
Combination Angiostatin and Endostatin Gene Transfer Induces Synergistic Antiangiogenic Activity in Vitro and Antitumor Efficacy in Leukemia and Solid Tumors in Mice
2001
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
2000 Standout
Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors
2002
Chronic immune activation and inflammation in the pathogenesis of aids and cancer
2002
HIV-1 V3 domain variation in brain and spleen of children with AIDS: Tissue-specific evolution within host-determined quasispecies
1991
Glycosylation Governs the Binding of Antipeptide Antibodies to Regions of Hypervariable Amino Acid Sequence within Recombinant gp120 of Human Immunodeficiency Virus Type 1
1990
Unfulfilled Promise of Endostatin in a Gene Therapy-Xenotransplant Model of Human Acute Lymphocytic Leukemia
2002
Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody
1992 Nature
Crystal structure of an HIV-binding recombinant fragment of human CD4
1990 StandoutNatureNobel
Membrane Type 1-Matrix Metalloproteinase Is Activated during Migration of Human Endothelial Cells and Modulates Endothelial Motility and Matrix Remodeling
2001
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
2003
A DNA metalloenzyme with DNA ligase activity
1995 StandoutNatureNobel
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis
2002
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
multifunctional enzymes in cancer
2006
Immunopathogenesis and immunotherapy in AIDS virus infections
2003
Immunopathogenic Mechanisms in Human Immunodeficiency Virus (HIV) Infection
1991
Adeno-associated virus–mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo
2002
The angiogenic switch in carcinogenesis
2009
The Hallmarks of Aging
2013 Standout
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011 StandoutNobel
Matrix metalloproteinases: multifunctional contributors to tumor progression
2000
Continuous Intravascular Secretion of Endostatin in Mice from Transduced Hematopoietic Stem Cells
2002
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
2002
Lack of collagen XVIII accelerates cutaneous wound healing, while overexpression of its endostatin domain leads to delayed healing
2008
An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis
2004
Extracellular matrix remodelling and cellular differentiation
1999
Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.
1994
Heterogeneous Vascular Dependence of Tumor Cell Populations
2001
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
2001
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Endogenous Inhibitors of Angiogenesis
2005
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4
1988
Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope
1994
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
2002
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
1991 StandoutNobel
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
1991
Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations
1990
Simian immunodeficiency viruses from central and western Africa: evidence for a new species-specific lentivirus in tantalus monkeys
1993
Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers.
1989
Growth factor–induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen
2001
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
1996
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
2000 StandoutNobel
Radiation therapy to a primary tumor accelerates metastatic growth in mice.
2001
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain
1991
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages
1999 StandoutNobel
Molecular Targets for AIDS Therapy
1990 Science
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation
1990
An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis
2004
Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity
1992
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
1990
Angiomotin
2001
Combinatorially selected guanosine-quartet structureis a potent inhibitor of human immunodeficiency virus envelope-mediated cellfusion.
1994
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
1994 StandoutNobel
A History of HIV Discovery
2002 StandoutScienceNobel
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.
1990
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
1994
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
1995
STUDIES OF THE AROMATIC CIRCULAR DICHROISM OF STAPHYLOCOCCAL NUCLEASE
1969 StandoutNobel
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
2000 StandoutNobel
Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.
1990
Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis
2000
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody
1991
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees
1990
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.
1995 StandoutNobel
ATP-dependent degradation of ubiquitin-protein conjugates.
1984 StandoutNobel
Immune Versus Natural Selection: Antibody Aldolases with Enzymic Rates But Broader Scope
1997 StandoutScienceNobel
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
2009
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.
1991
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
2000
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120
1989
Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
1990
Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice.
2002
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
1993
Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
1999
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
2003
Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing Determinant
1990 Science
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
1992
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections.
1994 StandoutNobel
Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage
1998 StandoutNobel
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis
2006
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
1993
Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals
2008
Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas.
2001
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Crystal Structures of an Antibody to a Peptide and Its Complex with Peptide Antigen at 2.8 Å
1990 Science
Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470.
2003
Ability of the V3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization: Correlation of Neutralization Sensitivity, Growth in Macrophages, and Decreased Dependence on CD4
2001
Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization
1992
Angiogenesis
2006
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
2006
A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.
1993 StandoutNobel
Differential effects of angiostatin, endostatin and interferon-α1 gene transfer on in vivo growth of human breast cancer cells
2002
Imaging the glycome
2008 StandoutNobel
Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus
1992
Neutralization of HIV‐1: a paradox of humoral proportions
1991
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
1995 StandoutNobel
Iron−Sulfur Cluster Biosynthesis: Toward an Understanding of Cellular Machinery and Molecular Mechanism
2004
Optical Activity of Biopolymers
1969 Nature
Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis
2002 Science
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
A Selective Turn-On Fluorescent Sensor for Imaging Copper in Living Cells
2005
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
1994
Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120
1991 Science
Mechanism by which the lectin actinohivin blocks HIV infection of target cells
2009 StandoutNobel
Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody
2020 StandoutNobel
Angiogenesis in Endocrine Tumors
2003
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells.
1991
Mechanistic Studies on Synthetic Fe−S-Based Clusters and Their Relevance to the Action of Nitrogenases
2005 StandoutNobel
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development
1997
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1
1990
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous.
1990
Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160
1992 StandoutNobel
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages
1991
Control of protein degradation in reticulocytes and reticulocyte extracts by hemin.
1980
Type-Restricted Neutralization of Molecular Clones of Human Immunodeficiency Virus
1988 Science
Progress toward active or passive HIV-1 vaccination
2016
LAV Revisited: Origins of the Early HIV-1 Isolates from Institut Pasteur
1991 StandoutScienceNobel
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.
2001
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans
1994
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism
1992
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
1995
Identification of the Envelope V3 Loop as the Primary Determinant of Cell Tropism in HIV-1
1991 Science
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein
1992
Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
1990
Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1
1994 StandoutNobel
Works of Kashi Javaherian being referenced
Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis
2005
C-Terminal Fragments of gpl20 and Synthetic Peptides from Five HTLV-III Strains: Prevalence of Antibodies to the HTLV-III-MN Isolate in Infected Individuals
1990
Characteristics of a Neutralizing Monoclonal Antibody to the HIV Envelope Glycoprotein
1988
Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice
2001
T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction
1989
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
1988
Zinc-dependent dimers observed in crystals of human endostatin
1998
Subunit interactions in the conformational change of horse apohemoglobin on binding of hemin
1968
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
1989
Oligomerization-Dependent Regulation of Motility and Morphogenesis by the Collagen Xviii Nc1/Endostatin Domain
2001
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
1999 Science
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope
1988
Broadly Neutralizing Antibodies Elicited by the Hypervariable Neutralizing Determinant of HIV-1
1990 Science
Endostatin therapy reveals a U-shaped curve for antitumor activity
2006
A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity
2005
Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates
2003
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
1992